On July 10, 2025, citing a drive to increase transparency, the Food and Drug Administration (“FDA”) published more than 200 complete response letters (CRLs) previously issued to companies that had submitted new drug...more
7/17/2025
/ Abbreviated New Drug Application (ANDA) ,
Biologics ,
Clinical Trials ,
Compliance ,
Disclosure Requirements ,
Drug Approvals ,
Drug Pricing ,
Enforcement Actions ,
Food and Drug Administration (FDA) ,
Investors ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Requirements ,
Transparency
Cozen O'Connor will host Health Care & Life Sciences 2025, our annual in-person seminar exploring critical issues impacting health care and life sciences businesses. Join attorneys and professionals from our Health Care &...more
11/1/2024
/ Best Practices ,
Centers for Medicare & Medicaid Services (CMS) ,
Chevron Deference ,
Chief Legal Officers ,
Continuing Legal Education ,
Corporate Transparency Act ,
Deadlines ,
Delaware ,
Enforcement Actions ,
Events ,
Food and Drug Administration (FDA) ,
Foreign Nationals ,
Health Care Providers ,
Healthcare Facilities ,
Healthcare Workers ,
Hiring & Firing ,
Life Sciences ,
New Jersey ,
Non-Compete Agreements ,
Pennsylvania ,
Private Equity ,
State Attorneys General ,
Workplace Violence